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cure achieved by hematopoietic stem cell transplant (HSCT). In
subsequent efforts to replicate this result, HIV rebounded post-
HSCT after withdrawal of antiretroviral therapy. Providing
HIV-specific immunity through adoptive T cell therapy may
prevent HIV rebound post-HSCT by eliminating newly in-
fected cells before they can seed systemic infection. Adoptive
T cell therapy has demonstrated success in boosting
Epstein-Barr virus and cytomegalovirus-specific immunity
post-HSCT, controlling viral reactivation. However, T cell
immunotherapies to boost HIV-specific immunity have been
limited by single-epitope specificity and minimal persistence
or efficacy in vivo. To improve this strategy, we sought to
generate allogeneic HIV-specific T cells from human leukocyte
antigen (HLA)-A02+HIV-negative adult or cord blood donors.
We focused on HLA-A02+ donors due to well-characterized
epitope restrictions observed in HIV+ populations. We show
that multi-antigen HIV-specific T cells can be generated from
naive T cells of both cord blood and adults using a reproducible
good manufacturing practice (GMP)-grade protocol. This
product lysed antigen-pulsed targets and suppressed active
HIV in vitro. Interestingly, these cells displayed broad epitope
recognition despite lacking recognition of the common
HLA-A02-restricted HIV epitope Gag SL9. This first
demonstration of functional multi-antigen HIV-specific
T cells has implications for improving treatment of HIV
through allogeneic HSCT.Received 31 January 2018; accepted 5 April 2018;
https://doi.org/10.1016/j.ymthe.2018.04.009.
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Current therapies for HIV are not curative. While antiretroviral
therapy (ART) successfully suppresses active infection, it does not erad-
icate latent HIV reservoirs. HIV cure strategies have focused on repli-
cating the successful allogeneic hematopoietic stem cell transplant
(HSCT) strategy used for the Berlin Patient,1,2 without success due to
viral rebound of the patients’ autologous viral reservoirs.3,4 The delayedviral rebound in the Boston patients suggests large reductions in the
HIV reservoir may allow HIV-specific T cells to control viral rebound
from the low levels of virus that persist post-transplant.
Several lines of evidence have firmly established that HIV-specific
T cell responses play a critical role in controlling HIV replication in in-
fected individuals. First, the emergence of HIV-specific CD8+ T cell
responses following infection is temporally associated with a 102- to
103-fold reduction in viremia during acute HIV infection.5–7 Second,
in the rhesus macaque simian immunodeficiency virus (SIV) infection
model, the depletion of CD8+ T cells has been shown to lead to a dra-
matic increase in viral load and rapid progression.8 Third, in infected
humans, it has been established that there are strong links between the
possession of certain major histocompatibility complex class I (MHC
class I) alleles and clinical progression.9,10 Fourth, CD8+ T cells exert
immune pressure on targeted epitopes, driving the emergence of
escape mutations, often at a fitness cost to the virus.11,12 Finally,
CD8+ T cells isolated fromHIV-infected individuals show a clear abil-
ity to eliminate infected cells and suppress viral replication in vitro.13
Thus, there is a strong rationale for enlisting HIV-specific T cells to
prevent viral rebound from any residual infected cells that may persist
following allogeneic HSCT and achieving a functional cure.
Adoptive T cell therapy post-HSCT has been successful in augment-
ing anti-viral immunity against chronic infections, such as cytomeg-
alovirus (CMV), Epstein-Barr virus (EBV),14–17 and associated
cancers, emphasizing the critical role T cells play in preventing viral
rebound. However, HIV is able to avoid immune pressures more
successfully than viral counterparts due to downregulation of MHC
Figure 1. HNA-Ts and CB-Ts Are Derived from the Naive Compartment,
Expand to Clinically Relevant Levels, and Demonstrate HIV Specificity
(A) HNA-T generated from the naive T cell compartment (red) produced HIV-specific
T cells compared to the non-naive compartment (blue). HNA-Ts displayed
significant IFNg secretion to GNP stimulation (p < 0.0001) compared to negative
controls CTL only and actin. (B) CB-Ts produced significant levels of IFNg in
response to GNP stimulation compared to CTL only (p < 0.0001). (C) HPA-Ts were
manufactured from HIV+ HLA-A02 individuals for use in comparative studies later
on and demonstrated significant IFNg secretion to GNP stimulation (p < 0.0001).class I and CD4 on infected cells, leading to suboptimal anti-HIV
CD8+ T cell responses.18 Despite efforts to augment anti-viral immu-
nity against HIV, T cell therapy has shown no efficacy, likely due to
infusion of single-epitope-specific clones that are susceptible to im-
mune escape19 or the absence of CD4+ T cells resulting in a lack of
persistence of infused cells.20 Furthermore, prevention strategies,
such as the HIV vaccine trial RV144,21 have been criticized for the
lack of eliciting strong T cell responses needed to achieve sustained
anti-HIV immunity.22,23 Thus, HIV-specific T cell therapies that
demonstrate the ability to persist and overcome immune escape
through recognition of multiple HIV epitopes will be critical to boost-
ing anti-HIV immunity.
The post-HSCT setting presents a unique opportunity where adoptive
HIV T cell therapy could target residual infected cells to prevent
rebound from the low levels of virus remaining. Furthermore, these
HIV-specific T cells may demonstrate better persistence compared
to the previous HIV immunotherapy trials mentioned, which had
no conditioning regimen. Based on the successful generation of
EBV- and CMV-specific T cells from virus-naive allogeneic do-
nors,24–27 we sought to generate HIV-specific T cells from HIV-sero-
negative adults and cord blood naive T cells in a good manufacturing
practice (GMP)-compliant manner. Whereas a closely related
HIV-negative donor could serve as the source of both the HSCT
and the adoptively transferred T cells, we also explored the use of
unrelated cord blood donors to generate HIV-specific T cells. There
are several benefits associated with the use of cord blood for HSCT,
including (1) less restrictive human leukocyte antigen (HLA) match-
ing requirements compared to their adult counterparts, reducing the
likelihood of graft-versus-host disease (GvHD);28 (2) rapid availabil-
ity; (3) flexibility for scheduling transplantation; and (4) lower risk of
relapse due to graft-versus-leukemia.28
To develop a widely applicable form of HIV immunotherapy, we
focused on HLA-A02+ donors, as this allele has one of the highest
frequencies across several ethnic groups and is dominant in HIV+ in-
dividuals infected with clade B HIV.29 Many immunodominant HIV
A02-restricted cytotoxic T lymphocyte (CTL) epitopes have been
identified and well characterized in HIV+ populations.30,31 Here,
we describe a novel approach to generating HIV-specific T cells
from HLA-A02+ HIV-naive adults (HNA-T) and cord blood
(CB-T), which demonstrate cytolytic capacity, suppress active HIV
in vitro, and broadly recognize epitopes from HIV antigens Gag,
Nef, and Pol.
RESULTS
HNA-Ts and CB-Ts Are Derived from the Naive T Cell
Compartment of HIV-Seronegative Adult Donors and Cord
Blood
Based on our previous success generating HIV-specific T cells from
HIV seronegative adults (HNA-Ts) (Figure S1),32 we sought to
determine whether HNA-Ts were generated from the naive T cell
compartment of healthy HIV seronegative adults, as seen in
CMV.17 Using magnetic selection, naive T cells were selected forCD3+CD45RA+CCR7+CD62L+ T cells (Figure S2). After the naive
selection step, T cells derived from both the naive compartment
and non-naive compartment were expanded in parallel using anti-
gen-presenting cells (APCs) pulsed with Gag, Nef, and Pol (GNP)
(Figure S1).
Naive T cell-derived HLA-A02+ HNA-T products expanded to clin-
ically relevant numbers (median = 100.5e6 cells; range = 23.8e6–
195.3e6 cells; Figure 1A). Interferon-gamma (IFNg) ELISPOT
against GNP pepmix confirmed that HIV-specific T cells were only
detected in T cell products derived from the naive T cell compart-
ment, because T cell products derived from non-naive T cells elicited
insignificant levels of IFNg in response to HIV antigens (Figure 1A).
The naive T cell-derived HNA-Ts showed HIV specificity
against Gag (mean = 158.83 IFNg SFC/1e5 cells; p < 0.0001),
Figure 2. Phenotyping of HIV-Specific T Cell Products Reveals Differences
in Composition and Minimal Expression of Exhaustion Markers
(A and B) HNA-Ts (A) and CB-Ts (B) display a primarily CD3+ phenotype, comprised
of substantial CD4+ and CD8+ subsets. (C) HPA-Ts are comprised of primarily
CD8+ T cells and NK/NKT cells, with a negligible CD4+ population. All three cohorts
display skewed effector memory responses and low expression of exhaustion
markers.Pol (mean = 122.87 IFNg SFC/1e5 cells; p = 0.016), and GNP pepmix 
(mean = 225.75 IFNg SFC/1e5 cells; p < 0.001) compared to irrelevant 
controls CTL alone (mean = 3.66 IFNg SFC/1e5 cells) and actin 
(mean = 5.37 IFNg SFC/1e5 cells; two-way ANOVA).
To further confirm that HIV-specific T cells can be derived from 
virus-naive donors, we repeated the approach using cord blood.28 
As shown in Figure 1B, CB-Ts were successfully expanded from 
cord blood (median = 56.8e6 cells; range = 25e6–132e6 cells). 
IFNg ELISPOT was performed to evaluate for HIV specificity. 
Increased IFNg production was observed in response to HIV 
Gag (mean = 136.05 IFNg SFC/1e5 cells; p = 0.023), Nef 
(mean = 196.86 IFNg SFC/1e5 cells; p = 0.0028) and Pol 
(mean = 233.59 IFNg SFC/1e5 cells; p = 0.0006), as well as the 
GNP pepmix (mean = 272.73 IFNg SFC/1e5 cells; p < 0.0001) 
compared to T cells alone (mean = 4.182 IFNg SFC/1e5 cells; 
2-way ANOVA; Figure 1B).
To evaluate whether the expansion and function of virus-naive 
donor-derived HIV-specific T cell products differed from 
products derived from HIV+ adults (HPA-Ts), we also generated 
HPA-Ts from HIV+ HLA-A02+ donors, based on established 
and US Food and Drug Administration (FDA)-approved 
(IND17562 and IND15984) protocols (Figure 1C).33,34 HPA-T prod-
ucts derived from HIV+ individuals expanded to clinically relevant 
numbers (median = 95.5e6 cells; range = 65.8e6–171.72e6 cells) 
similar to naive donor-derived HIV-specific T cells. Similarly, 
increased IFNg production was observed in response to HIV GNP 
pepmix stimulation (mean = 529.6 IFNg SFC/1e5 cells; p < 0.0001) 
compared to T cells alone (mean = 5.667 IFNg SFC/1e5 cells; two-way 
ANOVA).
HIV-Specific T Cell Products Derived from Virus-Naive Donors 
Have Higher CD4+ T Cell Frequencies Than Products Derived 
from HIV+ Donors
Phenotyping analysis of HNA-Ts, CB-Ts, and HPA-Ts revealed 
differences in the composition of the three product types (Figures 
2A–2C). Notably, HIV-specific T cells derived from HIV+ donors 
(HPA-T products) had low frequencies of CD4+ T cells (mean = 
7.65%; range = 0.69%–25.4%; Figure 2C) compared to HNA-T 
(mean = 38.4%; range = 13.4%–73.6%) and CB-T (mean = 23.35%; 
range = 3.8%–51.5%) products (Figures 2A and 2B). The frequencies 
of CD8+ T cells in HPA-T (mean = 44.1%; range = 16.9%–69.6%; 
n = 7), HNA-T (mean = 26.46%; range = 6.4%–59.8%; n = 6), and 
CB-T (mean = 49.48%; range = 13.0%–73.0%; n = 6) products were 
similar between products with higher levels of CD3neg/CD56+ 
natural killer (NK) cells (mean = 17.29%; range = 3.1%–42.5%) 
observed in HPA-T products (Figures 2A–2C). The memory popula-
tions of all three cohorts were skewed toward an effector memory 
(EM) phenotype, with a smaller population of T cells detected in all 
three product types that had a central memory (CM) phenotype 
(HPA-T-EM mean = 85.71%, range = 61.1%–97.8%; HNA-T-EM 
mean = 58.13%, range = 41.4%–77.8%; CB-T-EM mean = 69.9%, 
range = 49.5%–89.6%; Figures 2A–2C).HIV-Specific T Cells from All Sources Show Minimal Expression
of Exhaustion Markers
Flow analysis revealed similarly low expression levels of markers
associated with exhaustion in HPA-T and HNA-T products (PD-1:
HNA-T mean = 10.12% versus HPA-T mean = 10.13%; and
TIM-3: HNA-T mean = 7.63% versus HPA-T mean = 9.62%; Figures
2A and 2C). Moreover, CB-T products showed even lower levels
of exhaustion marker expression (mean: PD-1 = 6.8%; LAG-3 =
3.45%; TIM-3 = 3.05%; KLRG1 = 0.34%; CD57 = 1.08; Figure 2B).
CB-T, HNA-T, and HPA-T Products Exhibit Similar Cytolytic
Ability and Polyfunctionality In Vitro
Because exhaustion marker expression is also associated with cell
activation at low levels, we next evaluated the functionality of the
Figure 3. HNA-Ts and CB-Ts Demonstrate
Cytotoxicity, Suppression of Active HIV Infection
In Vitro, and Secretion of Multiple Cytokines
(A) HNA-Ts and CB-Ts display specific lysis of GNP-
pulsed autologous PHAb targets (red) at comparable
levels to HPA-T products. CB-Ts demonstrate dual EBV
specificity by specific lysis of unpulsed autologous LCLs
(green). Error bars represent the SD of triplicate values. (B)
HNA-Ts (n = 4) and CB-Ts (n = 4) demonstrate suppres-
sion of active HIV infection in vitro at E:T of 40:1 and 20:1
at day 7. Error bars represent the SD of triplicate values.
(C) HNA-T, CB-T, and HPA-T products secrete IL-2, IL-8,
IFNg, and TNF-a in response to GNP stimulation,
demonstrating product polyfunctionality. Error bars
represent the SD from the mean.HIV-specific T cell products to ensure they all elicited antigen-specific
cytolytic activity and were polyfunctional. In a chromium-release
cytotoxicity assay, CB-Ts were tested for their ability to lyse autolo-
gous lymphoblastoid cell line (LCL) or phytohemagglutinin (PHA)
blasts pulsed with GNP pepmix (Figure 3A). CB-Ts (n = 2) were
able to lyse LCL pulsed with GNP, with an effector-to-target ratio
(E:T) of 40:1 producing a mean specific lysis of 25.28% ± 4.22%.
CB-T also displayed lysis against unpulsed LCL (40:1 mean
13.63% ± 1.80%). CB-Ts were manufactured using autologous LCL
lines as APCs, which generated products with both HIV and EBV
specificity. Similarly, HNA-T products (n = 2) showed a mean lysis
of 26.53% ± 4.83% at an E:T ratio of 40:1 against autologous PHA
blasts pulsed with GNP, and HPA-T products showed a mean lysis
of 34.52% ± 3.75% at 40:1 (n = 3).To evaluate cytolytic activity against virus-
infected cells, CB-Ts were tested in a viral
inhibition assay to determine whether these
products suppress a laboratory strain of
HIV (SF162), in an in vitro model of active
HIV infection (Figure 3B). CB-Ts were
co-cultured at varying E:Ts with autologous
CD8-depleted peripheral blood mononuclear
cells (PBMCs) that had been infected with
SF162. Supernatants were measured for p24 by
ELISA as an indicator of HIV presence on
day 7. At E:T ratios of 40:1 and 20:1, CB-Ts
were able to significantly suppress HIV through
day 7 in vitro (p < 0.0001; two-way ANOVA)
compared to CD8-depleted HIV-infected cells
alone. This was similar to the levels of HIV
suppression we found in HNA-T products, as
shown in Figure 3B.
Products from all three cohorts were also tested
for product polyfunctionality in response to
GNP pepmix stimulation (Figure 3C). T cells
were stimulated with either actin (negative con-
trol) or GNP pepmix overnight, and cell culturesupernatants were tested by multiplex for levels of cytokines inter-
leukin-2 (IL-2), IL-8, IFNg, and tumor necrosis factor alpha
(TNF-a). Actin-stimulated T cell cytokine production levels were
negligible (data not shown). The production of similar cytokine levels
among the three cohorts in response to GNP stimulation suggests
these HIV seronegative, naive-derived T cell products have similar
polyfunctional capacity as those products generated from HIV+
individuals.
Epitope Mapping of HPA-T, HNA-T, and CB-T Products Reveals
Wide Epitope Breadth in HIV-Seronegative Individuals
We previously showed17 that CMVpp65-specific T cells from cord
blood and adult CMV seronegative donors did not recognize the ex-
pected typical peptides, such as the HLA-A02-restricted peptide
Table 1. HIV Naive Adult-Derived A02+ HNA-T Epitope Mapping
Product Name HLA Type Epitope Mapping
HNA-T HLA Class I HLA Class II NEF GAG POL
HNA-T #1
A02, 68; B07, 35;
C04, 07
DRB1 01, 15; DRB5 01;








A02, 03; B07, 50;
C06, 07
DRB1 07, 15; DRB4 01;
DRB5 01; DQA1 01, 02;





HNA-T #3 A02 known – – HQAISPRTLNAWVKV –
HNA-T #4
A02, 32; B40, 57;
C03, 06
DRB1 12, 13; DRB3 02, 03;







A02, 24; B35, 51;
C04, 14
DRB1 04, 11; DRB3 02;
DRB4 01; DQA1 03, 05;






A02, 68; B08, 35;
C04, 07
DRB1 03, 11; DRB3 01, 02;









A02, 01; B08, 51;
C07, 15
DRB1 04, 11; DRB3 02;
DRB4 01; DQA1 03, 05;





A02, 24; B39, 51;
C01, 07
DRB1 08, 11; DRB3 02;
DQA1 04, 05; DQB1 03, 04;
DPB1 02, 03
– – MASDFNLPPVVAKEI
HNA-Ts were mapped with overlapping 15 mers based on HIV-1 consensus sequences of Gag, Nef, and Pol. Known HLA-A02 epitopes (based on LAND) are shown in bold, and
confirmed 9-mer epitopes are italic, with unknown HLA restrictions.NLVPMVATV. To determine whether this result was unique to
CMVpp65 and NLV, we compared the peptide repertoires of HIV-
specific T cells from HLA-A02 HNA donors, CB-T donors, and
HIV+ donors using HIV gag peptide pools.
Products from all three donor cohorts were epitope mapped using
overlapping 15-mer peptides (AIDS Reagent Program). Products
were mapped using pool matrices with each pool consisting of
8–10 15-mer peptides. Cross-reactive pools containing the same
15-mer peptide were confirmed by individual 15-mer ELISPOTs,
as previously described.32 There were common 15mers mapped
among HNA-T (Table 1), CB-T (Table 2), and HPA-T (Table 3)
products.
Based on the Los Alamos National Laboratory (LANL) database of
known HIV epitopes35 and lists of HLA-associated selection on the
HIV proteome,36 the majority of HNA-T and CB-T products recog-
nized known epitopes in HIV+ populations. However, the commonly
recognized A02-restricted epitope SLYNTVATL (SL9) was not
recognized by any HIV-negative naive-derived products using this
screening approach.HLA A2-Restricted HIV-Epitope-Specific T Cells Derived from
Virus-Naive Donors Do Not Recognize the Typical HLA-A02 Gag
Epitope SL9 but Have High Functional Avidity
Knowing that SL9-specific T cells were not detected in 21/21 (10 HIV-
negative adults and 11 cord donors) HLA-A02+ virus-naive donor-
derived HIV-specific T cell products, and given that an estimated
75% of HIV-1-infected HLA-A02+ individuals recognize the Gag-
SL9 epitope,37 we next asked whether we could force the expansion
of SL9-specific T cells from these naive donors. For this, we stimulated
HLA-A02+ HIV-seronegative donor-derived PBMCs with APCs
pulsed with the SL9 9 mer alone versus the GNP pepmix (Figure 4).
As shown in Figure 4A, it was not possible to force Gag-SL9 specificity
in any of the HIV-seronegative donor-derived products (n = 3; Fig-
ure 4A). However, from the same donors, we produced HNA-T
and CB-T products specific for other Gag/Nef/Pol epitopes (Fig-
ure 4B). In contrast, and as expected, we could successfully expand
Gag-SL9-specific T cells from an HIV+ donor using the same meth-
odology (Figure 4C).
Because HIV-specific T cells derived fromHLAA2+ naive donors did
not recognize the expected SL9 Gag epitope and instead recognized
Table 2. HIV Naive Cord-Derived A02+ CB-T Epitope Mapping
Product Name HLA Type Epitope Mapping
CB-T HLA Class I HLA Class II NEF GAG POL
CB-T #1
A02, 29; B18, 51;
C05, 16
DRB1 03, 11; DRB3 02, 02;






A02, 24; B35, 35;
C01, 04
DRB1 04, 11; DRB3 02;
DRB4 01; DQA1 03, 05;







class I definitely WIPEWEFVNTPPLVK
CB-T #3
A02, 01; B27, 49;
C01, 07
DRB1 01, 01; DQA1 01, 01;





A02, 30; B15, 53;
C02, 04
DRB1 01, 11; DRB3 02;
DQA1 01, 01; DQB1 05,





A02, 68; B35, 51;
C04, 08
DRB1 14, 14; DRB3 01, 01;






A02, 33; B35, 51;
C04, 16
DRB1 13, 15; DRB3 03;




A02, 68; B15, 39;
C07, 07
DRB1 04, 07; DRB4 01, 01;








A02, 24; B13, 42;
C06, 17
DRB1 10, 11; DRB3 02;










CB-Ts were mapped with overlapping 15 mers based on HIV-1 consensus sequences of Gag, Nef, and Pol. Known HLA-A02 epitopes (based on LAND) are shown in bold, and
confirmed 9-mer epitopes are italic, with unknown HLA restrictions.other epitopes spanning HIV Gag, Nef, and Pol, we considered
whether the avidities of these T cell receptors for their respective pep-
tide/MHC complexes might differ depending on the donor source.
The functional avidity was determined by the EC50, or the concentra-
tion of peptide used to still provide one-half the maximummagnitude
of IFNg response. Functional avidity for HPA donor OM9 Gag SL9-
specific T cells revealed a low functional avidity (EC50 = 3.72 ng/mL;
Figure 4D).
To compare this functional avidity to the HIV-negative products, we
used limiting dilutions of peptides to test the functional avidity of two
HIV epitopes (one Gag and one Pol epitope) recognized by both
HNA-T and CB-T products. As shown in Figure S3A, for T cells
recognizing the Gag epitope HLVWASREL, the mean peptide con-
centration needed to induce a half-maximum IFNg response
(EC50) was 0.1 ng/mL in the CB-T-derived donor product compared
to an EC50 = 0.009 ng/mL observed with the seronegative adult donor
product. Additionally, naive donor-derived T cells that recognized the
Pol epitope KLVGKLNWA showed similar avidity irrespective of thedonor source: 0.01 ng/mL (CB-T donor) versus 0.03 ng/mL (adult
seronegative donor; Figure S3B), suggesting that HIV-naive donor-
derived HNA-Ts and CB-Ts may have higher functional avidity for
their cognate epitope compared to HPA-T products.
DISCUSSION
This is thefirst description of aGMP-compliant, reproducible platform
for generating HIV-specific T cells from HIV-seronegative, naive
T cells derived from adult or cord blood donors. These HNA-Ts and
CB-Ts demonstrated HIV specificity against epitopes spanning the
breadth of Gag, Nef, and Pol. Assessing functionality of these products,
HNA-Ts andCB-Ts suppressed activeHIV infection in vitro and lysed
autologous LCL and PHA blast targets pulsed with HIV pepmix. We
also observed a cytokine response dominated by production of IFNg
and TNF-a in response to HIV pepmix stimulation, suggestive of a
TH1 skewed response associated with intracellular pathogens, such as
HIV. IL-8 was also detected, normally involved in innate immune re-
sponses, such as neutrophil recruitment, and is not unexpected, based
on the diverse phenotypes of these HNA-T and CB-T products.
Table 3. HIV Positive-Derived A02+ HPA-T Epitope Mapping
Product Name HLA Type Epitope Mapping
HPA-T HLA Class I HLA Class II NEF GAG POL
HPA-T #1
A02, 03; B07, 40;
C03, 07
DRB1 04, 15; DQB1 03, 06;









A02, 03; B07, 52;
C07, 12
DRB1 15, 15; DRB5 01, 01;





A02, 02; B35, 44;
C04, 05
DRB1 01,04; DRB4 01;






A02, 26; B15, 44;
C02, 03
DRB1 04,11; DRB3 02;
DRB4 01; DQA1 03, 05;














A02, 32; B15, 40;
C02, 03;
DRB1 01, 14; DQB1 05, 05;









HPA-Ts were mapped with overlapping 15 mers based on HIV-1 consensus sequences of Gag, Nef, and Pol. HPA-T no. 2 (OM9) is the de-identified HIV+ donor from which SL9-
specific T cells are derived from in Figures 4C and 4D. Known HLA-A02 epitopes (based on LAND) are shown in bold with unknown HLA restrictions.Hanley et al.25,26 previously demonstrated that CMV-specific T cells
can be generated from cord blood, an obligatory source of naive
T cells. It was shown that HLA-A2+ CMV-specific T cells derived
from naive cord blood recognized atypical epitopes LQT and MLN,
whereas CMV-specific T cells generated from CMV+ donors recog-
nize the typical NLV epitope. That study demonstrated in vivo that
CMV-specific T cells recognizing atypical epitopes were protective,
with the presence of these T cells correlating with an absence of
CMV reactivation. Extending this model to HIV, we compared the
epitope recognition breadths of HNA-Ts, CB-Ts, and HPA-Ts
together with known HIV+ epitopes from the Los Alamos National
Database (LAND).
Interestingly, we were unable to generate Gag-SL9-specific T cells
from HLA-A2+ HIV-seronegative donors, suggesting that naive
donor-derived T cells recognize a different epitope repertoire from
HIV+ donors. This finding is similar to that of a study of 13 HIV-
uninfected individuals where a Gag vaccine did not produce Gag-SL9
responses37 and even forced expression failed to produce Gag-SL9-
specific T cells from healthy adult or cord donors. Nevertheless, our
approach was able to produce SL9-specific T cells from the HIV+ in-dividuals. Other investigators have also succeeded in generating SL9-
specific T cells from healthy cord blood, suggesting the type of APC
used for manufacturing may play a role in determining T cell speci-
ficity.38 Gag-SL9-specific T cells are commonly identified in chroni-
cally infected HIV+ individuals, but not during acute infection,
demonstrating the HIV epitope repertoire and resulting T cell
responses change over the course of HIV infection.39–41 In chronic
HIV infection, HIV+ individuals may be unable to control viral
load due to the accumulation of escape mutations in targeted
epitopes,11,12 T cell exhaustion,42–44 or the presence of CTLs
that recognize immunodominant epitopes, such as Gag SL9
(SLYNTVATL), a response negatively associated with viral load in
HIV progression but limited to chronic infection.41,45–47 This has sig-
nificant implications for developing non-exhausted T cell products
that target epitopes associated with multiple stages of HIV infection
and progression. Importantly, HNA-Ts and CB-Ts display a wide
breadth of specificity across Gag, Nef, and Pol antigens, offering exten-
sive coverage, and may be critical for preventing immune escape.
Despite this advantage, one concern with the infusion of HNA-T and
CB-T products is the presence of a notable CD4+ population with the
Figure 4. HLA-A02-Restricted HIV-Specific T Cells
Derived from Virus-Naive Donors Do Not Recognize
Gag SL9, Despite Forced ExpressionManufacturing
Methods
(A) No SL9-specific HNA-T or CB-T products were
generated using forced expression methods with SL9
9-mer peptide. (B) In comparison, GNP-specific HNA-Ts
and CB-Ts were generated from the same donors as a
control. (C) SL9-specific T cells were produced using
our manufacturing methods from an HIV-positive donor
(OM9), determined by IFNg ELISPOT. (D) SL9-specific
T cells show low functional avidity on IFNg ELISPOT,
stimulating with progressive dilutions of SL9 9-mer
peptide. In this figure, error bars represent the SD.potential to be infected by the recipient’s virus. To address this
concern, we are currently investigating two strategies to render
HIV-specific T cells resistant to HIV infection: gene modification
and selection of donors naturally resistant to HIV. Gene modification
approaches have shown promise in the HIV field. Several groups have
shown chimeric antigen receptors (CARs) can target conserved HIV
epitopes.48 Other groups have employed CRISPR technology and zinc
finger nucleases (ZFNs) to target HIV co-receptor CCR5 through
disruption of the host genome to prevent viral entry.49,50 Applying
these gene modification strategies to our HIV-specific T cells could
produce a potent cell product with the desired bi-functionality—cyto-
toxicity and resistance to infection.
We are also exploring generating HIV-specific T cells from HIV-
negative homozygous Delta32 CCR5 donors, who possess natural
resistance to R5-tropic HIV strains.51 The National Marrow Donor
Program (NMDP) and the German Cord Blood Bank (DKMS)
have typed homozygous Delta32 CCR5 cord units, providing a plat-
form for rapid availability and clinical translation.52Lastly, it is important to note that demon-
strating the persistence of these HIV-specific
T cells will be critical to produce durable,
long-term anti-HIV immunity, especially if
ART interruption is considered. The use of
other virus-specific T cells against EBV, CMV,
and adenovirus in a post-transplant setting has
demonstrated durability during this period of
immune suppression, with few patients experi-
encing recurring viral infection or progres-
sion.53 Translating this to the HIV setting, it is
critical that HIV-specific T cells persist to pro-
duce a durable long-term anti-HIV response,
particularly during immune reconstitution
post-HSCT, where low levels of residual reser-
voir virus may rebound if left unchecked.
Ultimately, we envision multiple platforms for
using HIV-specific T cells in the allogeneic
setting. First, HIV+ individuals with hemato-logic malignancies who receive an allogeneic-HSCT could receive
HIV-specific T cells from the same stem cell transplant donor to
help control viral rebound during immune reconstitution. Second,
HIV-specific T cells derived from HIV-seronegative sources could
be used in combination with latency-reversing agents to “shock and
kill” infected cells and reactivate latent infection for subsequent tar-
geting by T cells.54–56 The broad epitope recognition of HNA-Ts
and CB-Ts may be critical in this setting, as they can recognize
multiple HIV epitopes, reducing the chance of immune escape. These
potential applications for HIV-specific T cells from HIV-seronegative
donors set the stage for future cell therapy trials to validate the
efficacy of adoptive T cell therapy in HIV. Currently, we are also
exploring safety and efficacy of autologous HIV-specific T cells gener-
ated using the same approach in HIV+ individuals (NCT02208167
and NCT03212989).
In summary, we show that HIV-specific T cells can be generated from
the naive T cell compartment of HIV-seronegative adults and cord
blood. These products have wide epitope recognition, suppress HIV
in vitro, and demonstrate cytolytic abilities. This has important impli-
cations for HIV+ individuals undergoing stem cell transplantation for 
malignant disease where the HSCT donor can serve both as a source 




PBMCs were isolated from HIV-negative and HIV+ donors on ART 
with acute or chronic HIV infection (University of North Carolina, 
Chapel Hill, NC; University of Texas MD Anderson Cancer Center, 
Houston, TX; and The George Washington University, Washington, 
DC). All donations were obtained under informed consent approved 
at each institution. PBMCs were diluted 1:4 to 1:2 (blood: 1 PBS) 
and layered on top of 10–15 mL of Lymphocyte Separation Medium 
(MP Biomedicals, CA). Blood was spun for 30 min at 600 rpm at 
room temperature (RT). PBMCs were harvested from the lymphocyte 
layer and washed three times with 1 PBS prior to counting.
Generation of Dendritic Cells
PBMCs were plated for 2-hr adherence at 37C, after which non-
adherent cells were washed off and frozen. Dendritic cells (DCs) 
isolated from plastic adherence of PBMCs were fed with IL-4 
(1,000 U/mL) and granulocyte macrophage colony-stimulating factor 
(GM-CSF) (800 U/mL) for 6 days, added on day 1 and day 4. DCs 
were matured on day 7 with IL-4 (1,000 U/mL), GM-CSF 
(800 U/mL), IL-6 (100 ng/mL), TNF-a (10 ng/mL), IL-1b 
(10 ng/mL; all R&D Systems, MN), and Prostaglandin E1 
(1 mg/mL; Sigma-Aldrich, MO). DCs were harvested 24–48 hr after 
maturation for stimulation 1.
Generation of PHAbs for HNA-T Manufacturing
To generate PHA blasts (PHAbs), PBMCs were stimulated 
with PHA-P (5 mg/mL; Sigma-Aldrich, MO) in the presence of 
IL-2 on day 1. PHAbs were fed with IL-2 on day 3 and every 
2 or 3 days thereafter with IL-2. PHAbs were used as APCs in 
stimulations (stims) 2 and 3 for the HNA-T and HPA-T 
manufacturing protocols.
Generation of HIV-Specific T Cells from the HNA-Ts 
Compartment
A magnetic-activated cell sorting (MACS) column (Miltenyi Biotech, 
Germany) was used to positively select naive T cells from adult 
HIV-negative PBMCs selecting for CD3+CD45RA+CCR7+CD62L+. 
The negatively selected fraction was flushed through the magnetic 
column, and both the naive and non-naive T cell compartments 
were stimulated with antigen-coated DCs in stim 1 and subsequently 
expanded according to our established protocol.32,33 Irradiated 
PHAbs were used as APCs in stims 2 and 3. APCs were pulsed 
with HIV Gag, Nef, and Pol pepmixes. These were chosen as they 
are more conserved compared to Env and allow targeting of multiple 
stages of HIV infection, as Nef is expressed early whereas Gag and Pol 
are expressed later in infection.57 These overlapping HIV peptide 
libraries consisted of 15 mers, overlapping by 11 amino acids (JPT,Germany), based on consensus sequences of HIV-1. For stim 3, modi-
fied K562 cells were added, expressing co-stimulatory molecules
41-BBL, CD80, CD83, and CD86 (gift of Dr. Clio Rooney, Baylor,
TX) to aid in expansion. The ratios of cells cultured were as follows:
stim 1 (1:10; T:DC); stim 2 (1:4; T:PHAb); and stim 3 (1:1:4;
T:PHAb:K562).
Generation of Autologous LCLs for CB-T Manufacturing
Autologous LCL lines were generated from cord blood mononuclear
cells (CBMCs) to serve as APCs for the generation of CB-Ts. 5e6
PBMCs were pelleted and resuspended in 200 mL of live B95-8 EBV
(produced by infected marmoset cells). This B95-8-CBMC mixture
was then resuspended in 2 mL of cRPMI containing cyclosporine A
(1 mg/mL). On a 96-well plate, 5 wells were plated at 200 mL each
of the viral cell suspension. The remaining 1 mL was diluted to
2 mL with cRPMI containing cyclosporine and plated in 10 wells of
200 mL each. The cells were monitored weekly, and as the wells
became confluent, cells were expanded into 24-well plates, T25 flasks,
and ultimately T75 flasks. The generation of autologous LCL lines
required from 1 to 2 months.
Generation of CB-Ts
The protocol for the generation of CB-Ts is similar to that of the
HNA-Ts,32,33 with several key differences: (1) K562s were not used
to expand CB-Ts in the 3rd stimulation; (2) at stim 1, IL-7, IL-12,
and either IL-15 or IL-21 was used to assist in proliferation and
expansion of T cells; and (3) autologous LCLs replaced PHA blasts
as the APCs for the second and third stimulation at a LCL:T cells ratio
of 1:1 (Figure S1).
IFNg ELISPOT Assay and Epitope Mapping
No peptide or the irrelevant peptide, actin (JPT, Germany), was used
as negative control. Staphylococcus enterotoxin B (SEB) was used as a
positive control (Sigma-Aldrich, MO). T cells were plated at 1e5/well
on IFNg-coated ELISPOT plates (Millipore, NJ). Positive responses
are defined as having more than double the spot-forming cells
(SFCs) obtained in the negative controls, with a minimum of 50
IFNg SFC/1e5 cells/well. For epitope mapping, the 15-mer peptides
overlapping by 11 amino acids spanning the consensus region of
the Gag, Nef, and Pol antigens were pooled and used according to pre-
viously published matrices.32 Using the matrices, cross-reactive pools
were analyzed for common 15-mer epitopes, and these 15-mer epi-
topes were then individually tested on ELISPOT to confirm epitope
specificity.
HLA Epitope Specificity: IFNg ELISPOT
Based on epitope-mapping ELISPOTs, expanded HIV-specific
T cells were tested for HLA specificity to Gag, Nef, Pol, or
individual peptides. For HLA blocking, 1  105 cells/well were
treated with monoclonal mouse anti-human HLA class I or
HLA class II antibody (Dako, Agilent, CA) in a 96-well round-
bottom plate for 1 hr at 37C. Treated cells were transferred to
ELISPOT plate, stimulated with peptide, and developed as previ-
ously described.
Flow Cytometry Phenotyping and Exhaustion Panels
Flow for phenotyping and exhaustion panels were run on the
MACSQUANT Analyzer (Miltenyi Biotech, Germany) with analysis
done with FlowJo software (FlowJo, OR). For the phenotyping, the
following antibodies were used: anti-CD3; CD4; CD8; CD45RA;
CD45RO; CD56; CD16; and CD62L (Miltenyi Biotech, Germany).
For exhaustion phenotyping, the following antibodies were used:
anti-CD3; PD-1; LAG-3; TIM-3; KLRG1; and CD57. For isotype
controls, the recommended isotype for each of the previous anti-
bodies was purchased and used. 1e6 cells were stained per condition,
incubated for 30 min at 4C, washed twice with fluorescence-
activated cell sorting (FACS) buffer (2%–5% FBS/1 PBS), and run
on the MACSQUANT.Multiplex Assay
To assess polyfunctionality of T cell products, a multiplex assay was
run using the Bio-plex Pro Human 17-plex Cytokine Assay kit
(Bio-Rad, CA). HPA-T, HNA-T, and CB-T products were thawed
overnight with IL-2 (50 U/mL) on day 1. On day 2, T cells were
washed and plated at 1e6 cells/well with 1 ml of corresponding
pepmix: actin; GNP; or SEB. On day 3, supernatants were harvested
from the wells and plated on the multiplex plate. The multiplex
protocol provided by Bio-Rad was followed for the 17-plex kit, and
the plate was analyzed for concentrations of cytokines, based on the
standard curves produced.Viral Inhibition Assay
CD8-depleted PBMCs were activated in IL-2 (50 U/mL) and PHA
(2 mg/mL) before being infected with HIV laboratory strain SF162. In-
fected target cells were co-cultured for 5 days with expanded HIV-
specific T cells or unexpanded CD8 T cells that were isolated using
magnetic beads (Miltenyi Biotech, Germany) added at 1:2 E:T and
20:1 E:T. The following conditions were used as controls: uninfected
CD8-depleted PBMCs; infected CD8-depleted PBMCs alone; antire-
trovirals (ARVs); ARVs + expanded HIV-specific T cells; and
expanded CMV- and EBV-specific T cells. Day 5 supernatants were
measured for HIV-1 gag p24 concentration by ELISA (ABL, Rock-
ville, MD). The ARVs used in combination were indinavir and ralte-
gravir (Selleck Chemicals, TX).Cytotoxicity Assay
The cytolytic activity of HPA-T products was determined with a
chromium-51-release assay. Autologous PHAb targets were pulsed
with nothing (negative control) or Gag/Nef/Pol pepmix and
incubated with chromium 51 for 1 hr. Targets were then washed
3 times and co-cultured with autologous HPA-Ts at E:Ts of 40:1,
20:1, 10:1, and 5:1. Targets alone were plated as a spontaneous release
control. Targets mixed with 1% Triton X (Sigma-Aldrich, MO) were
plated as a maximum release control. Targets were co-cultured with
effectors for 4 or 5 hr at 37C. Plates were spun, and supernatant
was collected onto a Luma plate (PerkinElmer, MA). Plate was
left overnight, and Cr51 release was measured the next morning in
a MicroBeta2 counter. Specific lysis % was measured as (experimentalrelease  spontaneous release)/(maximum release  spontaneous
release)  100.Functional Avidity
Functional avidity of HPA-T, HNA-T, and CB-T products were
tested using limiting dilutions of individual peptides (NIH AIDS
Reagent Program and GenScript, NJ). Once our T cell products
were confirmed as specific against individual 15-mer peptides
(AIDS Reagent Program), the individual 9-/10-mer peptides within
the 15-mer sequence were ordered (GenScript, NJ) to determine the
exact epitope responsible. T cells were plated on IFNg ELISPOT at
1e5 cells/well with limiting dilutions of peptide to determine the
EC50. ELISPOTs were sent out for analysis for unbiased spot counting
(Zellnet, NJ).HLA Typing
Samples were sent for high-resolution HLA typing (Kashi Clinical
Laboratories, OR).Statistical Analysis
Two-way ANOVA with Holm-Sidak correction was used to deter-
mine statistical significance of IFNg release on ELISPOT in response
to HIV antigens compared to the negative control as well as signifi-
cance of HIV suppression in viral inhibition assay. Means, medians,
and ranges were provided where applicable.SUPPLEMENTAL INFORMATION
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